Published in Am J Respir Crit Care Med on January 14, 2010
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis (2013) 1.27
Management of malignant pleural mesothelioma-The European experience. J Thorac Dis (2014) 1.14
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res (2014) 1.00
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res (2013) 0.91
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One (2013) 0.90
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open (2014) 0.90
Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers (2013) 0.88
Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. Clin Proteomics (2013) 0.87
Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. Mol Clin Oncol (2013) 0.86
Malignant mesothelioma: development to therapy. J Cell Biochem (2014) 0.85
Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung (2013) 0.84
Discovery of new biomarkers for malignant mesothelioma. Curr Pulmonol Rep (2015) 0.83
Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers (Basel) (2010) 0.82
Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure. Bioanalysis (2015) 0.81
Update in lung cancer and oncological disorders 2010. Am J Respir Crit Care Med (2011) 0.78
Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study. Cancer Sci (2015) 0.77
Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease. Biomark Insights (2014) 0.77
Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma. PLoS One (2011) 0.76
The continual search for ideal biomarkers for mesothelioma: the hurdles. J Thorac Dis (2013) 0.76
Unusual presentation and location pleural malignant mesothelioma. BMJ Case Rep (2013) 0.75
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. BMC Cancer (2017) 0.75
Mesothelioma - Update on Diagnostic Strategies. Clin Pulm Med (2012) 0.75
Mesothelioma treatment: Are we on target? A review. J Adv Res (2014) 0.75
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer (2017) 0.75
Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. BMJ Open (2016) 0.75
Multimodality therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 0.75
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl Lung Cancer Res (2017) 0.75
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget (2017) 0.75
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Management of lung nodules detected by volume CT scanning. N Engl J Med (2009) 6.79
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA (2010) 4.08
Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med (2013) 3.47
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Testing for recombinant human erythropoietin. J Appl Physiol (1985) (2008) 3.02
Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta (2006) 2.97
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (2007) 2.85
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol (2012) 2.57
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol (2004) 2.44
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28
Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial. Am J Respir Crit Care Med (2007) 2.26
False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood (2006) 2.06
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90
Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer (2006) 1.89
The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol (2003) 1.72
Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transplant (2005) 1.72
EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer (2008) 1.69
Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc (2002) 1.68
EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol (2009) 1.60
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol (2012) 1.59
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Hypersensitivity pneumonitis due to molds in a saxophone player. Chest (2010) 1.58
Development of an affordable dye-stained microalbuminuria screening test. Nephrol Dial Transplant (2008) 1.50
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer (2011) 1.48
Expressed wishes and incidence of euthanasia in advanced lung cancer patients. Eur Respir J (2012) 1.46
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43
Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J (2013) 1.42
Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease. Clin Chem Lab Med (2015) 1.41
Mediastinal emphysema and small cell lung cancer (SCLC): a case-report. Lung Cancer (2005) 1.38
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol (2013) 1.32
Projected future climate change and Baltic Sea ecosystem management. Ambio (2015) 1.32
Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer (2006) 1.31
Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin (2011) 1.29
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer (2004) 1.28
Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology (2010) 1.27
The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodules. Chest (2012) 1.23
Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta (2008) 1.23
A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl (2008) 1.20
A statistical approach to central monitoring of data quality in clinical trials. Clin Trials (2012) 1.17
The relevance of marine chemical ecology to plankton and ecosystem function: an emerging field. Mar Drugs (2011) 1.16
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer (2010) 1.15
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer (2009) 1.11
Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.11
A meta-analysis on depression and subsequent cancer risk. Clin Pract Epidemiol Ment Health (2007) 1.10
Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem (2010) 1.09
Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med (2004) 1.09
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol (2008) 1.09
Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta (2004) 1.08
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. J Clin Oncol (2006) 1.07
Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg (2010) 1.07
'Black Spots' and hyaline pleural plaques on the parietal pleura of 150 urban necropsy cases. Am J Surg Pathol (2002) 1.07
Temporary cyst formation in phytoplankton: a response to allelopathic competitors? Environ Microbiol (2004) 1.07
Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol (2012) 1.05
Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int (2009) 1.05
Increased urinary neutrophil gelatinase associated lipocalin in urinary tract infections and leukocyturia. Clin Chem Lab Med (2011) 1.05
Change in the actin cytoskeleton during seismonastic movement of Mimosa pudica. Plant Cell Physiol (2006) 1.04
[High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer]. Gan To Kagaku Ryoho (2011) 1.03
Epidemiology of chronic pain in denmark and sweden. Pain Res Treat (2012) 1.01
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol (2011) 1.00
Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys (2002) 1.00
Surgery in mesothelioma--where do we go after MARS? J Thorac Oncol (2013) 1.00
Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int J Radiat Oncol Biol Phys (2004) 0.99
ChemR23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia. PLoS Pathog (2011) 0.99
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res (2003) 0.99
Adjusting for centre heterogeneity in multicentre clinical trials with a time-to-event outcome. Pharm Stat (2014) 0.97
Proposed criteria for mixed-dust pneumoconiosis: definition, descriptions, and guidelines for pathologic diagnosis and clinical correlation. Hum Pathol (2004) 0.97
Unexpected response of a pulmonary blastoma on radiotherapy: a case report and review of the literature. Lung Cancer (2002) 0.97
Genomic copy number determines functional expression of {beta}-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 0.97
Flow cytometry as a new method to quantify the cellular content of human saliva and its relation to gingivitis. Clin Chim Acta (2002) 0.97
Haptoglobin polymorphism and lacunar stroke. Curr Neurovasc Res (2008) 0.96
Haptoglobin polymorphism and infection. Adv Clin Chem (2010) 0.95
Endoscopic and endobronchial ultrasonography according to the proposed lymph node map definition in the seventh edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol (2009) 0.95
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol (2013) 0.95
Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer? Eur J Anaesthesiol (2011) 0.95